PMID: 6992074May 1, 1980Paper

Acute lymphoblastic leukemia

Pediatric Clinics of North America
D R Miller

Abstract

The improved outlook in childhood leukemia can be attributed to more accurate diagnosis, better supportive care, the use of drug combinations to achieve and maintain remission, and prophylactic therapy to prevent central nervous system leukemia. With the best treatment available today, 65 to 70 per cent of children are in complete continuous remission five years after diagnosis. Recent advances in biology, diagnosis, and treatment which have contributed to this progress are reviewed.

Citations

Dec 15, 1984·Cancer·S D SmithW Snodgrass
Jan 1, 1984·Issues in Comprehensive Pediatric Nursing·B L Fife, W Lancaster
Jan 1, 1983·Medical and Pediatric Oncology·D J GanickW Borcherding
May 1, 1989·American Journal of Hematology·J BlattM Horn
Nov 1, 1982·Acta paediatrica Scandinavica·G Gustafsson, A Kreuger
Nov 1, 1982·Australian Journal of Ophthalmology·M H Bremner, J Wright
Feb 1, 1981·Archives of Disease in Childhood·J M Chessells
Feb 1, 1981·Archives of Disease in Childhood·D W Bullimore
Jan 1, 1986·Pediatric Hematology and Oncology·G Gustafsson, A Kreuger
May 1, 1996·Pediatric Hematology and Oncology·V ShantaK R Rajalekshmy
Apr 3, 2007·Indian Journal of Pediatrics·A SettinY Al-Tonbary
May 23, 2008·Pediatric Emergency Care·Jonathan Singer, Susan Henry
Oct 1, 1985·Clinical EEG (electroencephalography)·C M EpsteinA H Ragab
Apr 1, 1985·Hematological Oncology·S H SwerdlowR D Collins
Aug 1, 1984·European Journal of Pediatrics·G Gaedicke, H G Drexler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.